Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1273 to 1281 of 1281 entries
Sorted by: Best Match Show Resources per page
Evaluation of diazepam as a drug treatment for water hemlock (Cicuta species) poisoning in Spanish goats.

Toxicon : official journal of the International Society on Toxinology

Green BT, Stonecipher CA, Welch KD, Lee ST, Cook D.
PMID: 34871669
Toxicon. 2022 Jan 15;205:79-83. doi: 10.1016/j.toxicon.2021.12.003. Epub 2021 Dec 03.

Water hemlocks (Cicuta spp.) are toxic members of the Apiaceae plant family. The best drug treatment for the convulsions associated with acute water hemlock poisoning in livestock and humans has not been determined experimentally. This work compared the therapeutic...

Cite
Green BT, Stonecipher CA, Welch KD, et al. Evaluation of diazepam as a drug treatment for water hemlock (Cicuta species) poisoning in Spanish goats. Toxicon. 2021;205:79-83doi: 10.1016/j.toxicon.2021.12.003.
Green, B. T., Stonecipher, C. A., Welch, K. D., Lee, S. T., & Cook, D. (2022). Evaluation of diazepam as a drug treatment for water hemlock (Cicuta species) poisoning in Spanish goats. Toxicon : official journal of the International Society on Toxinology, 20579-83. https://doi.org/10.1016/j.toxicon.2021.12.003
Green, Benedict T, et al. "Evaluation of diazepam as a drug treatment for water hemlock (Cicuta species) poisoning in Spanish goats." Toxicon : official journal of the International Society on Toxinology vol. 205 (2022): 79-83. doi: https://doi.org/10.1016/j.toxicon.2021.12.003
Green BT, Stonecipher CA, Welch KD, Lee ST, Cook D. Evaluation of diazepam as a drug treatment for water hemlock (Cicuta species) poisoning in Spanish goats. Toxicon. 2022 Jan 15;205:79-83. doi: 10.1016/j.toxicon.2021.12.003. Epub 2021 Dec 03. PMID: 34871669.
Copy Download .nbib Format: NLM
Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy.

Journal of anaesthesiology, clinical pharmacology

Singh T, Kathuria S, Jain R, Sood D, Gupta S.
PMID: 33840934
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):518-523. doi: 10.4103/joacp.JOACP_440_19. Epub 2021 Jan 18.

BACKGROUND AND AIMS: Pregabalin has been used in various studies for postoperative pain relief in varying doses. However, there is no conclusive evidence to support a safe and effective dose of pregabalin. The present study was designed to compare...

Cite
Singh T, Kathuria S, Jain R, et al. Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol. 2021;36(4):518-523doi: 10.4103/joacp.JOACP_440_19.
Singh, T., Kathuria, S., Jain, R., Sood, D., & Gupta, S. (2020). Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy. Journal of anaesthesiology, clinical pharmacology, 36(4), 518-523. https://doi.org/10.4103/joacp.JOACP_440_19
Singh, Tanveer, et al. "Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy." Journal of anaesthesiology, clinical pharmacology vol. 36,4 (2020): 518-523. doi: https://doi.org/10.4103/joacp.JOACP_440_19
Singh T, Kathuria S, Jain R, Sood D, Gupta S. Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):518-523. doi: 10.4103/joacp.JOACP_440_19. Epub 2021 Jan 18. PMID: 33840934; PMCID: PMC8022042.
Copy Download .nbib Format: NLM
A comparative study of desflurane versus sevoflurane in obese patients: Effect on recovery profile.

Journal of anaesthesiology, clinical pharmacology

Bansal T, Garg K, Katyal S, Sood D, Grewal A, Kumar A.
PMID: 33840938
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):541-545. doi: 10.4103/joacp.JOACP_307_19. Epub 2021 Jan 18.

BACKGROUND AND AIMS: Anesthesia in obese patients is difficult due to associated comorbidities and altered physiology. Desflurane and sevoflurane have a low fat-blood solubility coefficient and are better suited in these patients to achieve a rapid emergence. We studied...

Cite
Bansal T, Garg K, Katyal S, et al. A comparative study of desflurane versus sevoflurane in obese patients: Effect on recovery profile. J Anaesthesiol Clin Pharmacol. 2021;36(4):541-545doi: 10.4103/joacp.JOACP_307_19.
Bansal, T., Garg, K., Katyal, S., Sood, D., Grewal, A., & Kumar, A. (2020). A comparative study of desflurane versus sevoflurane in obese patients: Effect on recovery profile. Journal of anaesthesiology, clinical pharmacology, 36(4), 541-545. https://doi.org/10.4103/joacp.JOACP_307_19
Bansal, Tania, et al. "A comparative study of desflurane versus sevoflurane in obese patients: Effect on recovery profile." Journal of anaesthesiology, clinical pharmacology vol. 36,4 (2020): 541-545. doi: https://doi.org/10.4103/joacp.JOACP_307_19
Bansal T, Garg K, Katyal S, Sood D, Grewal A, Kumar A. A comparative study of desflurane versus sevoflurane in obese patients: Effect on recovery profile. J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):541-545. doi: 10.4103/joacp.JOACP_307_19. Epub 2021 Jan 18. PMID: 33840938; PMCID: PMC8022057.
Copy Download .nbib Format: NLM
Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance.

The Lancet regional health. Europe

Pritchard E, Jones J, Vihta KD, Stoesser N, Matthews PPC, Eyre DW, House T, Bell JI, Newton PJN, Farrar J, Crook PD, Hopkins S, Cook D, Rourke E, Studley R, Diamond PI, Peto PT, Pouwels KB, Walker PAS.
PMID: 34927119
Lancet Reg Health Eur. 2022 Feb;13:100282. doi: 10.1016/j.lanepe.2021.100282. Epub 2021 Dec 12.

BACKGROUND: The COVID-19 pandemic is rapidly evolving, with emerging variants and fluctuating control policies. Real-time population screening and identification of groups in whom positivity is highest could help monitor spread and inform public health messaging and strategy.METHODS: To develop...

Cite
Pritchard E, Jones J, Vihta KD, et al. Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance. Lancet Reg Health Eur. 2021;13:100282doi: 10.1016/j.lanepe.2021.100282.
Pritchard, E., Jones, J., Vihta, K. D., Stoesser, N., Matthews, P. P. C., Eyre, D. W., House, T., Bell, J. I., Newton, P. J. N., Farrar, J., Crook, P. D., Hopkins, S., Cook, D., Rourke, E., Studley, R., Diamond, P. I., Peto, P. T., Pouwels, K. B., Walker, P. A. S. (2022). Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance. The Lancet regional health. Europe, 13100282. https://doi.org/10.1016/j.lanepe.2021.100282
Pritchard, Emma, et al. "Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance." The Lancet regional health. Europe vol. 13 (2022): 100282. doi: https://doi.org/10.1016/j.lanepe.2021.100282
Pritchard E, Jones J, Vihta KD, Stoesser N, Matthews PPC, Eyre DW, House T, Bell JI, Newton PJN, Farrar J, Crook PD, Hopkins S, Cook D, Rourke E, Studley R, Diamond PI, Peto PT, Pouwels KB, Walker PAS. Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance. Lancet Reg Health Eur. 2022 Feb;13:100282. doi: 10.1016/j.lanepe.2021.100282. Epub 2021 Dec 12. PMID: 34927119; PMCID: PMC8665900.
Copy Download .nbib Format: NLM
Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach.

BMJ open

Mistry H, Morris S, Dyer M, Kotseva K, Wood D, Buxton M.
PMID: 23065443
BMJ Open. 2012 Oct 11;2(5). doi: 10.1136/bmjopen-2012-001029. Print 2012.

OBJECTIVE: To investigate the longer-term cost-effectiveness of a nurse-coordinated preventive cardiology programme for primary prevention of cardiovascular disease (CVD) compared to routine practice from a health service perspective.DESIGN: A matched, paired cluster-randomised controlled trial.SETTING: Six pairs of general practices...

Cite
Mistry H, Morris S, Dyer M, et al. Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. BMJ Open. 2012;2(5)doi: 10.1136/bmjopen-2012-001029.
Mistry, H., Morris, S., Dyer, M., Kotseva, K., Wood, D., Buxton, M. (2012). Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. BMJ open, 2(5), . https://doi.org/10.1136/bmjopen-2012-001029
Mistry, Hema, et al. "Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach." BMJ open vol. 2,5 (2012). doi: https://doi.org/10.1136/bmjopen-2012-001029
Mistry H, Morris S, Dyer M, Kotseva K, Wood D, Buxton M. Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. BMJ Open. 2012 Oct 11;2(5). doi: 10.1136/bmjopen-2012-001029. Print 2012. PMID: 23065443; PMCID: PMC3488746.
Copy Download .nbib Format: NLM
Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation.

Frontiers in molecular biosciences

Wharton KA, Wood D, Manesse M, Maclean KH, Leiss F, Zuraw A.
PMID: 34386519
Front Mol Biosci. 2021 Jul 27;8:672531. doi: 10.3389/fmolb.2021.672531. eCollection 2021.

No abstract available.

Cite
Wharton KA, Wood D, Manesse M, et al. Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Front Mol Biosci. 2021;8:672531doi: 10.3389/fmolb.2021.672531.
Wharton, K. A., Wood, D., Manesse, M., Maclean, K. H., Leiss, F., & Zuraw, A. (2021). Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Frontiers in molecular biosciences, 8672531. https://doi.org/10.3389/fmolb.2021.672531
Wharton, Keith A, et al. "Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation." Frontiers in molecular biosciences vol. 8 (2021): 672531. doi: https://doi.org/10.3389/fmolb.2021.672531
Wharton KA, Wood D, Manesse M, Maclean KH, Leiss F, Zuraw A. Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Front Mol Biosci. 2021 Jul 27;8:672531. doi: 10.3389/fmolb.2021.672531. eCollection 2021. PMID: 34386519; PMCID: PMC8353449.
Copy Download .nbib Format: NLM
Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Vaccines

Wilson WC, Faburay B, Trujillo JD, Ragan I, Sunwoo SY, Morozov I, Shivanna V, Balogh A, Urbaniak K, McVey DS, Bold D, Gaudreault NN, Schirtzinger EE, Ma W, Richt JA.
PMID: 34358166
Vaccines (Basel). 2021 Jul 06;9(7). doi: 10.3390/vaccines9070748.

Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that causes periodic outbreaks of abortion in ruminant species and hemorrhagic disease in humans in sub-Saharan Africa. These outbreaks have a significant impact on veterinary and public health. Its...

Cite
Wilson WC, Faburay B, Trujillo JD, et al. Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle. Vaccines (Basel). 2021;9(7)doi: 10.3390/vaccines9070748.
Wilson, W. C., Faburay, B., Trujillo, J. D., Ragan, I., Sunwoo, S. Y., Morozov, I., Shivanna, V., Balogh, A., Urbaniak, K., McVey, D. S., Bold, D., Gaudreault, N. N., Schirtzinger, E. E., Ma, W., & Richt, J. A. (2021). Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle. Vaccines, 9(7), . https://doi.org/10.3390/vaccines9070748
Wilson, William C, et al. "Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle." Vaccines vol. 9,7 (2021). doi: https://doi.org/10.3390/vaccines9070748
Wilson WC, Faburay B, Trujillo JD, Ragan I, Sunwoo SY, Morozov I, Shivanna V, Balogh A, Urbaniak K, McVey DS, Bold D, Gaudreault NN, Schirtzinger EE, Ma W, Richt JA. Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle. Vaccines (Basel). 2021 Jul 06;9(7). doi: 10.3390/vaccines9070748. PMID: 34358166; PMCID: PMC8310273.
Copy Download .nbib Format: NLM
Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke.

Science advances

Lemmerman LR, Balch MHH, Moore JT, Alzate-Correa D, Rincon-Benavides MA, Salazar-Puerta A, Gnyawali S, Harris HN, Lawrence W, Ortega-Pineda L, Wilch L, Risser IB, Maxwell AJ, Duarte-Sanmiguel S, Dodd D, Guio-Vega GP, McTigue DM, Arnold WD, Nimjee SM, Sen CK, Khanna S, Rink C, Higuita-Castro N, Gallego-Perez D.
PMID: 33741587
Sci Adv. 2021 Mar 19;7(12). doi: 10.1126/sciadv.abd4735. Print 2021 Mar.

Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to substantial functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here,...

Cite
Lemmerman LR, Balch MHH, Moore JT, et al. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Sci Adv. 2021;7(12)doi: 10.1126/sciadv.abd4735.
Lemmerman, L. R., Balch, M. H. H., Moore, J. T., Alzate-Correa, D., Rincon-Benavides, M. A., Salazar-Puerta, A., Gnyawali, S., Harris, H. N., Lawrence, W., Ortega-Pineda, L., Wilch, L., Risser, I. B., Maxwell, A. J., Duarte-Sanmiguel, S., Dodd, D., Guio-Vega, G. P., McTigue, D. M., Arnold, W. D., Nimjee, S. M., Sen, C. K., Khanna, S., Rink, C., Higuita-Castro, N., & Gallego-Perez, D. (2021). Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Science advances, 7(12), . https://doi.org/10.1126/sciadv.abd4735
Lemmerman, Luke R, et al. "Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke." Science advances vol. 7,12 (2021). doi: https://doi.org/10.1126/sciadv.abd4735
Lemmerman LR, Balch MHH, Moore JT, Alzate-Correa D, Rincon-Benavides MA, Salazar-Puerta A, Gnyawali S, Harris HN, Lawrence W, Ortega-Pineda L, Wilch L, Risser IB, Maxwell AJ, Duarte-Sanmiguel S, Dodd D, Guio-Vega GP, McTigue DM, Arnold WD, Nimjee SM, Sen CK, Khanna S, Rink C, Higuita-Castro N, Gallego-Perez D. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Sci Adv. 2021 Mar 19;7(12). doi: 10.1126/sciadv.abd4735. Print 2021 Mar. PMID: 33741587; PMCID: PMC7978431.
Copy Download .nbib Format: NLM
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary clinical trials communications

Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW.
PMID: 34401600
Contemp Clin Trials Commun. 2021 Aug 04;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep.

BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent that selectively detects malignant tissue and can be used in real time to guide tumor resection. The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of BLZ-100...

Cite
Yamada M, Miller DM, Lowe M, et al. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021;23:100830doi: 10.1016/j.conctc.2021.100830.
Yamada, M., Miller, D. M., Lowe, M., Rowe, C., Wood, D., Soyer, H. P., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J. M., Brandt, G., Griffin, P., Spelman, L., & Prow, T. W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary clinical trials communications, 23100830. https://doi.org/10.1016/j.conctc.2021.100830
Yamada, Miko, et al. "A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients." Contemporary clinical trials communications vol. 23 (2021): 100830. doi: https://doi.org/10.1016/j.conctc.2021.100830
Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021 Aug 04;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep. PMID: 34401600; PMCID: PMC8355837.
Copy Download .nbib Format: NLM
Showing 1273 to 1281 of 1281 entries